Gold rally may be losing steam but no major correction seen: DB
JUPITER, Fla. - Dyadic International, Inc. (NASDAQ:DYAI) announced Monday it has reached milestone payments in its collaborations with Proliant Health & Biologicals and Inzymes ApS, as the biotechnology company continues its transition toward commercial operations.
The company received a $250,000 milestone payment from Inzymes following productivity improvements in non-animal dairy enzymes during the third quarter. Additionally, Dyadic achieved a $500,000 milestone with Proliant for recombinant human albumin productivity, with payment expected in the fourth quarter. These developments contribute to the company’s strong financial health metrics, including a solid current ratio of 2.02 and healthy gross margins of nearly 60%.
The Proliant partnership is advancing toward commercialization, with product sampling already underway and a commercial launch targeted for late 2025 and early 2026.
In the food and nutrition sector, Dyadic signed a term sheet for developing non-animal human alpha-lactalbumin for infant nutrition. The company has also begun sampling non-animal bovine alpha-lactalbumin for food applications and is engaged in licensing discussions with potential partners.
Dyadic’s recombinant DNase I has met performance benchmarks for activity and purity, validating its potential use in molecular biology, diagnostics, and biopharma applications. The company is currently producing research-grade DNase I to support direct sales and OEM supply opportunities.
"The third quarter featured substantial progress throughout our portfolio," said Joe Hazelton, President and Chief Operating Officer of Dyadic Applied BioSolutions, in the press release.
Dyadic uses proprietary microbial platforms to produce recombinant proteins for partners across life sciences, food and nutrition, and bio-industrial markets.
In other recent news, Dyadic International reported its financial results for the second quarter of 2025, highlighting significant revenue growth. The company posted revenue of $967,000, slightly exceeding expectations, though it reported a net loss with an EPS of -0.06, which matched forecasts. Despite these financial results, the company’s stock experienced a decline, driven by investor concerns over ongoing losses and future profitability. Additionally, Craig-Hallum initiated coverage on Dyadic International with a Buy rating and set a price target of $5.00. The research firm noted Dyadic’s strategic shift towards commercializing its proprietary C1-cell protein production platform and Dapibus platforms. These developments are part of Dyadic’s recent efforts to transition from a focus on research and development to commercial operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.